‘RE:fine drugs’: an interactive dashboard to access drug repurposing opportunities

Moosavinasab, Soheil; Patterson, Jeremy; Strouse, Robert; Rastegar-Mojarad, Majid; Regan, Kelly; Payne, Philip R. O.; Huang, Yungui; Lin, Simon

doi:10.1093/database/baw083

Cited by 47 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DrugSig is a web resource that allows for prioritizing potential drug repurposing opportunities, allowing for users to submit up-and down-regulated genes from pre-computed disease differential expression profiles 35 . RE:fine drugs is an interactive dashboard that precalculates potential drug repurposing opportunities combining information from previously published GWAS and PheWAS results 36 . Users can search for a drug name, disease name, or gene symbol to see suggestions based on these levels of evidence.…”

Section: Availabilitymentioning

confidence: 99%

OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features

Zeng

Glicksberg

Newbury

et al. 2019

Preprint

View full text Add to dashboard Cite

One approach to precision medicine is to discover drugs that target molecularly defined diseases. Voluminous cancer patient gene expression profiles have been accumulated in public databases, enabling the creation of a cancer-specific expression signature. By matching this signature to perturbagen-induced gene expression profiles from large drug libraries, researchers can prioritize small molecules that present high potency to reverse expression of signature genes for further experimental testing of their efficacy. This approach has proven to be an efficient and cost-effective way to identify efficacious drug candidates. However, the success of this approach requires multiscale procedures, imposing significant challenges to many labs. Therefore, we present OCTAD: an open workplace for virtually screening compounds targeting precise cancer patient groups using gene expression features. We release OCTAD as a web portal and standalone R workflow to allow experimental and computational scientists to easily navigate the tool. In this work, we describe this tool and demonstrate its potential for precision medicine.

show abstract

Section: Availabilitymentioning

confidence: 99%

OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features

Zeng

Glicksberg

Newbury

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…evaluated the potential for drug repurposing by linking current drug‐targeted genes in DrugBank to the gene–phenotype associations in the PheWAS catalog . They validated the disease indications for drugs in 127 cases, but also identified 2,583 that strongly supported potential novel drug–disease associations, available within a cataloged database to the public . There are several factors that can influence the ability for a drug–disease identified in PheWAS and poised for drug repurposing to come to fruition.…”

Section: Use Of Gwas and Phewas To Identify Opportunities For Drug Rementioning

confidence: 99%

“…73 They validated the disease indications for drugs in 127 cases, but also identified 2,583 that strongly supported potential novel drug-disease associations, available within a cataloged database to the public. 79 There are several factors that can influence the ability for a drugdisease identified in PheWAS and poised for drug repurposing to come to fruition. In particular, methods must be developed to narrow the results to candidate drug-disease pairs that are supported in the literature or by mechanistic knowledge.…”

Section: Use Of Gwas and Phewas To Identify Opportunities For Drug Rementioning

confidence: 99%

Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records

Robinson

Denny

Roden

et al. 2017

Clinical Translational Sci

View full text Add to dashboard Cite

“…The “Drug Repurposing Hub” (http://www.broadinstitute.org/repurposing), consisting of both a reliable physical source for approved drugs, as well as a virtual library describing their characteristics, will certainly help to identify new uses for the existing pantheon . There are also a variety of other publicly available resources that can assist repurposing, including RepurposingDB, Re:fine Drugs, or repoDB …”

Section: Introductionmentioning

confidence: 99%

Repurposing approved drugs on the pathway to novel therapies

Schein

2019

Medicinal Research Reviews

View full text Add to dashboard Cite

The time and cost of developing new drugs have led many groups to limit their search for therapeutics to compounds that have previously been approved for human use. Many “repurposed” drugs, such as derivatives of thalidomide, antibiotics, and antivirals have had clinical success in treatment areas well beyond their original approved use. These include applications in treating antibiotic‐resistant organisms, viruses, cancers and to prevent burn scarring. The major theoretical justification for reusing approved drugs is that they have known modes of action and controllable side effects. Coadministering antibiotics with inhibitors of bacterial toxins or enzymes that mediate multidrug resistance can greatly enhance their activity. Drugs that control host cell pathways, including inflammation, tumor necrosis factor, interferons, and autophagy, can reduce the “cytokine storm” response to injury, control infection, and aid in cancer therapy. An active compound, even if previously approved for human use, will be a poor clinical candidate if it lacks specificity for the new target, has poor solubility or can cause serious side effects. Synergistic combinations can reduce the dosages of the individual components to lower reactivity. Preclinical analysis should take into account that severely ill patients with comorbidities will be more sensitive to side effects than healthy trial subjects. Once an active, approved drug has been identified, collaboration with medicinal chemists can aid in finding derivatives with better physicochemical properties, specificity, and efficacy, to provide novel therapies for cancers, emerging and rare diseases.

show abstract

‘RE:fine drugs’: an interactive dashboard to access drug repurposing opportunities

Cited by 47 publications

References 24 publications

OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features

OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features

Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records

Repurposing approved drugs on the pathway to novel therapies

Contact Info

Product

Resources

About